Research programme: tryptophan hydroxylase inhibitors - Karos Pharmaceuticals

Drug Profile

Research programme: tryptophan hydroxylase inhibitors - Karos Pharmaceuticals

Alternative Names: KAR 5417; TPH1 inhibitors

Latest Information Update: 20 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karos Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant carcinoid syndrome

Most Recent Events

  • 13 Apr 2016 Preclinical development in malignant carcinoid syndrome in USA (unspecified route)
  • 13 Apr 2016 Karos Pharmaceuticals plans proof-of-concept studies in in two or more additional indications 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top